South Africa on fire: closing innings at the WTO TRIPS Council (10 December 2020)

UPDATE (16 December 2020): The WTO General Council is meeting from Wednesday, 16 December 2020 to Friday, 18 December 2020 to discuss a number of matters including e-commerce, cotton, and TRIPS Council matters. Under agenda item 13, the Chair of… Continue Reading

Foundational mRNA patents are subject to the Bayh-Dole Act provisions

Katalin Karikó and Drew Weissman are often described as the pioneers of the mRNA discoveries that underpin the first COVID-19 vaccines. In 2005 both scientists published a paper reporting that a slightly tweaked version of mRNA that can be administered… Continue Reading

KEI comments to FDA on Prospective Exclusive Patent License for Diagnostic for SARS, SARS-CoV-2, Other Viruses, Bacteria and Bacterial Serovar, to Advion

To: Ken Millburne Technology Transfer Program Food and Drug Administration Via email: Kenneth.millburne@fda.hhs.gov From: James Love Knowledge Ecology International 1621 Connecticut Avenue NW, Suite 500 Washington, DC 20009 https://keionline.org Date: November 30, 2020 Re: Prospective Grant of an Exclusive Patent… Continue Reading

WTO TRIPS Council – 20 November 2020 – South Africa’s defense of the TRIPS waiver

On Friday, 20 November 2020, the World Trade Organization (WTO) convened an informal, virtual meeting of the TRIPS Council to discuss a proposal (IP/C/W/669) co-sponsored by Eswatini, India, Kenya, and South Africa for a waiver from certain provisions of the… Continue Reading

Regeneron COVID-19 Contract Weakens the Government’s Rights in Data

On November 5, 2020, Regeneron Pharmaceuticals published a redacted version of the contract awarding the company $450 million taxpayers’ dollars for the large-scale manufacture of Regeneron’s investigational COVID-19 antibody treatment. The contract uses Other Transactions Authority to weaken the U.S.… Continue Reading

U.S. Government funding of Lilly’s LY-CoV555 antibody against COVID-19

Lilly recently requested an emergency use authorization for LY-CoV555, an antibody treatment candidate against COVID-19. Like other COVID-19 candidates, the discovery of LY-CoV555 was heavily supported by the U.S. government. The government of Canada has also awarded millions to manufacture… Continue Reading